KNSA insider trading
NasdaqGS HealthcareKiniksa Pharmaceuticals International, plc — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Company website: www.kiniksa.com
KNSA insider activity at a glance
FilingIQ has scored 779 insider transactions for KNSA since May 29, 2018. The most recent filing in our index is dated May 1, 2026.
Across the full history, 7 open-market purchases
and 175 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on KNSA insider trades is 67.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest KNSA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for KNSA?
- FilingIQ tracks 779 Form 4 insider transactions for KNSA (Kiniksa Pharmaceuticals International, plc), covering filings from May 29, 2018 onwards. 114 of those were filed in the last 90 days.
- Are KNSA insiders net buyers or net sellers?
- Across the full Form 4 history for KNSA, 7 transactions (1%) were open-market purchases and 175 (22%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does KNSA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is KNSA in?
- Kiniksa Pharmaceuticals International, plc (KNSA) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $3.49B.
Methodology & sources
Every KNSA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.